Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2022
|
| _version_ | 1797107874829172736 |
|---|---|
| author | Simpson, CR Kerr, S Katikireddi, SV McCowan, C Ritchie, LD Pan, J Stock, SJ Rudan, I Tsang, RSM de Lusignan, S Hobbs, FDR Akbari, A Lyons, RA Robertson, C Sheikh, A |
| author_facet | Simpson, CR Kerr, S Katikireddi, SV McCowan, C Ritchie, LD Pan, J Stock, SJ Rudan, I Tsang, RSM de Lusignan, S Hobbs, FDR Akbari, A Lyons, RA Robertson, C Sheikh, A |
| author_sort | Simpson, CR |
| collection | OXFORD |
| description | We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2. The incidence rate ratio (IRR) for idiopathic thrombocytopenic purpura (ITP) 14-20 days post-ChAdOx1 second dose was 2.14, 95% confidence interval (CI) 0.90-5.08. The incidence of ITP post-second dose ChAdOx1 was 0.59 (0.37-0.89) per 100,000 doses. No evidence of an increased risk of CVST was found for the 0-27 day risk period (IRR 0.83, 95% CI 0.16 to 4.26). However, few (≤5) events arose within this risk period. It is perhaps noteworthy that these events all clustered in the 7-13 day period (IRR 4.06, 95% CI 0.94 to 17.51). No other associations were found for second dose ChAdOx1, or any association for second dose BNT162b2 vaccination. Second dose ChAdOx1 vaccination was associated with increased borderline risks of ITP and CVST events. However, these events were rare thus providing reassurance about the safety of these vaccines. Further analyses including more cases are required to determine more precisely the risk profile for ITP and CVST after a second dose of ChAdOx1 vaccine. |
| first_indexed | 2024-03-07T07:21:47Z |
| format | Journal article |
| id | oxford-uuid:bdb7338c-318b-4d40-8f33-5bcd263e2740 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:21:47Z |
| publishDate | 2022 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:bdb7338c-318b-4d40-8f33-5bcd263e27402022-10-14T15:39:50ZSecond-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in ScotlandJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bdb7338c-318b-4d40-8f33-5bcd263e2740EnglishSymplectic ElementsSpringer Nature2022Simpson, CRKerr, SKatikireddi, SVMcCowan, CRitchie, LDPan, JStock, SJRudan, ITsang, RSMde Lusignan, SHobbs, FDRAkbari, ALyons, RARobertson, CSheikh, AWe investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2. The incidence rate ratio (IRR) for idiopathic thrombocytopenic purpura (ITP) 14-20 days post-ChAdOx1 second dose was 2.14, 95% confidence interval (CI) 0.90-5.08. The incidence of ITP post-second dose ChAdOx1 was 0.59 (0.37-0.89) per 100,000 doses. No evidence of an increased risk of CVST was found for the 0-27 day risk period (IRR 0.83, 95% CI 0.16 to 4.26). However, few (≤5) events arose within this risk period. It is perhaps noteworthy that these events all clustered in the 7-13 day period (IRR 4.06, 95% CI 0.94 to 17.51). No other associations were found for second dose ChAdOx1, or any association for second dose BNT162b2 vaccination. Second dose ChAdOx1 vaccination was associated with increased borderline risks of ITP and CVST events. However, these events were rare thus providing reassurance about the safety of these vaccines. Further analyses including more cases are required to determine more precisely the risk profile for ITP and CVST after a second dose of ChAdOx1 vaccine. |
| spellingShingle | Simpson, CR Kerr, S Katikireddi, SV McCowan, C Ritchie, LD Pan, J Stock, SJ Rudan, I Tsang, RSM de Lusignan, S Hobbs, FDR Akbari, A Lyons, RA Robertson, C Sheikh, A Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland |
| title | Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland |
| title_full | Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland |
| title_fullStr | Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland |
| title_full_unstemmed | Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland |
| title_short | Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland |
| title_sort | second dose chadox1 and bnt162b2 covid 19 vaccines and thrombocytopenic thromboembolic and hemorrhagic events in scotland |
| work_keys_str_mv | AT simpsoncr seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT kerrs seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT katikireddisv seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT mccowanc seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT ritchield seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT panj seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT stocksj seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT rudani seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT tsangrsm seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT delusignans seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT hobbsfdr seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT akbaria seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT lyonsra seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT robertsonc seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland AT sheikha seconddosechadox1andbnt162b2covid19vaccinesandthrombocytopenicthromboembolicandhemorrhagiceventsinscotland |